Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0027-4.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 32.70K | 80.30K | 96.30K | 166.70K | 102.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.50K | 80.80K | 96.60K | 167.20K | 113.50K |
| Operating Income | -31.50K | -80.80K | -96.60K | -167.20K | -113.50K |
| Income Before Tax | -654.50K | -3.37M | -278.20K | -475.20K | -791.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -654.50K | -3.37M | -278.20K | -475.20K | -791.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 53.50K | 67.20K | 68.30K | 66.50K | 55.10K |
| Net Income | -600.90K | -3.30M | -209.80K | -408.70K | -736.00K |
| EBIT | -31.50K | -80.80K | -96.60K | -167.20K | -113.50K |
| EBITDA | -- | -- | -- | -- | -110.30K |
| EPS Basic | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 407.30M | 407.29M | 401.60M | 399.38M | 350.59M |
| Average Diluted Shares Outstanding | 407.30M | 407.29M | 401.60M | 399.38M | 350.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |